This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Race Announces Presentation of Preclinical Breast Cancer Zantrene Study at the 2021 Hunter Cancer Research Symposium
5 November 2021– Race Oncology Limited (“Race”) congratulates Dr Joshua Brzozowski from the laboratory of Associate Professor Nikki Verrills, University of Newcastle, for winning the Best Poster Prize in the Biomarkers and Targeted Therapy section at the Hunter Cancer Research Symposium on November 4, 2021. The presentation entitled “Preclinical efficacy of bisantrene for the treatment…
-
Race Initiates University of Newcastle Collaboration to Develop a Genomics-based Companion Diagnostic for Zantrene
3 November 2021 – Race Oncology Limited (“Race”) is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle to develop a companion diagnostic to support the use of Zantrene® as a precision oncology treatment, targeting the FTO protein. Eminent genomics researcher, Professor Murray Cairns of the…
-
Race Submits Human Ethics Application to Commence Phase 2 Extramedullary AML & MDS Trial
1 November 2021 – Race Oncology Limited (“Race”) is pleased to announce it has submitted the first human ethics application to the Hunter New England Human Research Ethics Committee (NSW, Australia) seeking approval to commence an open label Phase 2 clinical trial of Zantrene (bisantrene dihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or…
-
Race Initiates FTO Biomarker Research Collaboration with Chaim Sheba Israel
27 October 2021 – Race Oncology Limited (“Race”) is pleased to announce it has entered into a research collaboration with Dr Dan Dominissini of the Chaim Sheba Medical Center, Israel to analyse clinical patient samples from the ongoing Zantrene® Phase 1b/2 trial in relapsed/refractory Acute Myeloid Leukaemia (R/R AML) for FTO and FTO-related biomarkers (ASX…
-
Race secures sixth US patent for Zantrene
United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF 19 October 2021 – Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US patent no. 11,147,800) on its cancer drug, Zantrene® (bisantrene dihydrochloride), by the United States Patent…
-
Race secures fifth US patent for Zantrene
Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US 11,135,201) from the United States Patent and Trademarks Office (USPTO) for its cancer drug, Zantrene® (bisantrene dihydrochloride). This is Race’s fifth patent granted for Zantrene in the United States. “This latest US patent provides Race with additional protection around…
-
Zantrene kills melanoma cancer cells that overproduce FTO
Race Oncology Limited (“Race”) is pleased to share interim results from our collaborative preclinical melanoma research program with the University of Newcastle (ASX Announcement: 19 Mar 2021). Eminent melanoma researchers, Professor Xu Dong Zhang and Associate Professor Lei Jin, are leading the project. This program is exploring the use of Zantrene® (bisantrene dihydrochloride) as a…
-
Sed autem id et
Officia suscipit voluptates dolore ea Labore dolores ut perspiciatis expedita. Dolorum architecto praesentium suscipit consequatur nihil mollitia. Magnam ea quidem aliquid unde ut molestiae necessitatibus eum. Ut expedita et ipsa rerum. Ea aut itaque error cum magnam consequatur aut quia. Rerum et iusto assumenda occaecati quaerat et. Earum eum voluptatibus veritatis nihil dolores officia libero.…
-
First Patient Dosed in Phase 1b/2 AML Trial at Chaim Sheba Medical Center Israel
09 August 2021 – Race Oncology Limited (“Race”) is pleased to announce that the first patient has been dosed in the Phase 1b/2 trial in relapsed/refractory Acute Myeloid Leukaemia (ASX Announcement: 22 June 2021). This investigator-led trial supervised by Professor Arnon Nagler will use Zantrene® (bisantrene dihydrochloride) in a novel three drug combination which has…